US482828A
(en)
|
|
1892-09-20 |
|
Locomotive |
US568822A
(en)
|
|
1896-10-06 |
|
Lamp-wick and art of producing same |
US624012A
(en)
|
|
1899-05-02 |
|
Stenciling or decorative device |
AU527784B2
(en)
|
1978-05-26 |
1983-03-24 |
Bang, Hans Olaf Dr. |
Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
|
JPS57112593A
(en)
|
1980-12-26 |
1982-07-13 |
Koken Boring Machine Co |
Lathe drill
|
US4377526A
(en)
|
1981-05-15 |
1983-03-22 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid and its esters
|
CA1239587A
(en)
|
1983-10-24 |
1988-07-26 |
David Rubin |
Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
|
US4526902A
(en)
|
1983-10-24 |
1985-07-02 |
Century Laboratories, Inc. |
Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
|
US4933351A
(en)
|
1983-10-31 |
1990-06-12 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carbox amides useful as inhibitors of leukoriene biosynthesis
|
US4822803A
(en)
|
1983-10-31 |
1989-04-18 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carboxylic acid hydrazides useful as inhibitors of leukotriene biosynthesis
|
US4745127A
(en)
|
1983-10-31 |
1988-05-17 |
Merck Frosst Canada, Inc. |
Benzyl esters of benzofuran-2-carboxylic acids useful as inhibitors of leukotriene biosynthesis
|
US4663347A
(en)
|
1983-10-31 |
1987-05-05 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
|
US4673684A
(en)
|
1984-04-04 |
1987-06-16 |
Terumo Corporation |
Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
|
JPS6135356A
(ja)
|
1984-07-27 |
1986-02-19 |
Nippon Oil & Fats Co Ltd |
血液脂質脂肪酸の分析方法
|
US4728735A
(en)
|
1984-10-15 |
1988-03-01 |
Merck & Co., Inc. |
10,11-dihydro-dibenzo-[b,f][1,4]-thiazepin derivatives
|
GB8505285D0
(en)
|
1985-03-01 |
1985-04-03 |
Beecham Group Plc |
Compounds
|
US4624964A
(en)
|
1985-03-27 |
1986-11-25 |
E. I. Du Pont De Nemours And Company |
Aryl oxo-alkynoates as 5-lipoxygenase inhibitors
|
SU1600627A3
(ru)
|
1985-05-08 |
1990-10-15 |
Е.И.Дюпон Де Немур Энд Компани (Фирма) |
Способ получени 2-замещенных 1-нафтолов
|
US4803279A
(en)
|
1985-05-23 |
1989-02-07 |
Smithkline Beckman Corporation |
1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
|
US5008390A
(en)
|
1985-05-23 |
1991-04-16 |
Smithkline Beckman Corporation |
Compounds for preparing 6-phenyl-2,3-dihydroimidazo[2,1-b]-thiazoles and corresponding thiazines
|
US4602023A
(en)
|
1985-06-03 |
1986-07-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
US4786755A
(en)
|
1985-06-03 |
1988-11-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
GB8515522D0
(en)
|
1985-06-19 |
1985-07-24 |
Beecham Group Plc |
Compounds
|
EP0347509A1
(en)
|
1988-06-21 |
1989-12-27 |
Century Laboratories Inc. |
A process of extraction and purification of polyunsaturated fatty acids from natural sources
|
US4939169A
(en)
|
1985-09-20 |
1990-07-03 |
The Upjohn Company |
1,4-naphthalenediol and 1,4-hydroquinone derivatives
|
JPS63501288A
(ja)
|
1985-09-20 |
1988-05-19 |
ジ・アップジョン・カンパニ− |
1,4−ナフタレンジオ−ルおよび1,4−ヒドロキノン誘導体
|
JPS6272657A
(ja)
|
1985-09-27 |
1987-04-03 |
Terumo Corp |
アミド誘導体およびこれを含有する5−リポキシゲナ−ゼ作用阻害剤
|
US4694018A
(en)
|
1985-11-29 |
1987-09-15 |
G. D. Serale & Co. |
Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
|
US4728656A
(en)
|
1985-12-12 |
1988-03-01 |
Smithkline Beckman Corporation |
2,2-alkyldiylbis(thio)bis(imidazoles) useful for inhibition of the 5-lipoxygenase pathway
|
US4751310A
(en)
|
1985-12-12 |
1988-06-14 |
Smithkline Beckman Corporation |
Inhibition of the 5-lipoxygenase pathway
|
US4847270A
(en)
|
1985-12-12 |
1989-07-11 |
Smithkline Beckman Corporation |
Inhibition of the 5-lipoxygenase pathway utilizing certain 2,2'-alkyldiyl bis(thio)bis-imidazoles and derivatives
|
US4719218A
(en)
|
1985-12-12 |
1988-01-12 |
Smithkline Beckman Corporation |
Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
|
US4686231A
(en)
|
1985-12-12 |
1987-08-11 |
Smithkline Beckman Corporation |
Inhibition of 5-lipoxygenase products
|
US5134150A
(en)
|
1985-12-12 |
1992-07-28 |
Smithkline Beecham Corporation |
Inhibition of the 5-lipoxygenase pathway
|
US4755524A
(en)
|
1986-01-31 |
1988-07-05 |
G. D. Searle & Co. |
Novel phenolic thioethers as inhibitors of 5-lipoxygenase
|
US4711903A
(en)
|
1986-01-31 |
1987-12-08 |
G. D. Searle & Co. |
Phenolic thioethers as inhibitors of 5-lipoxygenase
|
IE59813B1
(en)
|
1986-05-09 |
1994-04-06 |
Warner Lambert Co |
Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
|
US4794114A
(en)
|
1986-08-19 |
1988-12-27 |
Smithkline Beckman Corporation |
Inhibition of interleukin-1 production by monocytes and/or macrophages
|
US4672075A
(en)
|
1986-08-26 |
1987-06-09 |
E. R. Squibb & Sons |
7-Oxabicyclo(2.2.1)heptane hydroxamic acid derivatives useful as antiinflammatory, antiasthma and antipsoriatic agents
|
US4920098A
(en)
|
1986-09-17 |
1990-04-24 |
Baxter International Inc. |
Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
|
US4695586A
(en)
|
1986-09-23 |
1987-09-22 |
E. R. Squibb & Sons, Inc. |
7-oxabicyclo(2.2.1)heptane-based derivatives useful as antiinflammatory, antiasthma and antipsoratic agents
|
US4695585A
(en)
|
1986-09-23 |
1987-09-22 |
E. R. Squibb & Sons, Inc. |
7-oxabicyclo(2.2.1)heptane analogs useful as inhibitors of 5-lipoxygenase and cyclooxygenase
|
DE3789435T2
(de)
|
1986-12-26 |
1994-10-20 |
Sagami Chem Res |
Verfahren zur Herstellung von Eicosapentaensäure.
|
US4861798A
(en)
|
1986-12-29 |
1989-08-29 |
Bristol-Myers Company |
Lipoxygenase inhibitory compounds
|
US4731382A
(en)
|
1986-12-29 |
1988-03-15 |
Bristol-Myers Company |
Lipoxygenase inhibitory phenylalkanohydroxamic acids
|
JPS63185390A
(ja)
|
1987-01-27 |
1988-07-30 |
Suntory Ltd |
藻類によるエイコサペンタエン酸の製造方法
|
US5250565A
(en)
|
1987-02-10 |
1993-10-05 |
Abbott Laboratories |
Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
|
US4877881A
(en)
|
1987-04-06 |
1989-10-31 |
Warner-Lambert Company |
Process of preparing pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors
|
US4889941A
(en)
|
1987-04-23 |
1989-12-26 |
Fisons Corporation |
Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase
|
US5252333A
(en)
|
1987-04-27 |
1993-10-12 |
Scotia Holdings Plc |
Lithium salt-containing pharmaceutical compositions
|
US4801611A
(en)
|
1987-05-07 |
1989-01-31 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
US5162365A
(en)
|
1987-05-07 |
1992-11-10 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
US5036105A
(en)
|
1987-05-07 |
1991-07-30 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
GB8711802D0
(en)
|
1987-05-19 |
1987-06-24 |
Fujisawa Pharmaceutical Co |
Dithioacetal compounds
|
US4835190A
(en)
|
1987-06-05 |
1989-05-30 |
G. D. Searle & Co. |
Phenolic thioethers as inhbitors of 5-lipoxygenase
|
US4835189A
(en)
|
1987-06-05 |
1989-05-30 |
G. D. Searle & Co. |
Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
|
US5198468A
(en)
|
1987-06-24 |
1993-03-30 |
Efamol Holdings Plc |
Essential fatty acid composition
|
US5086052A
(en)
|
1987-07-17 |
1992-02-04 |
Abbott Laboratories |
Substituted 1,4,5,6-tetrahydro-2H-pyridazin-3-one and -3-thione compounds having lipoxygenase inhibitory activity
|
US4970210A
(en)
|
1987-07-17 |
1990-11-13 |
Abbott Laboratories |
Triazinone lipoxygenase compounds
|
US4843095A
(en)
|
1987-08-07 |
1989-06-27 |
Century Laboratories, Inc. |
Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
|
FR2621038B1
(fr)
|
1987-09-28 |
1989-12-29 |
Rhone Poulenc Sante |
Derives d'alcadienes, leurs preparations, les medicaments les contenant et produits intermediaires
|
EP0380669B1
(en)
|
1987-10-16 |
1994-03-23 |
Terumo Kabushiki Kaisha |
Isoprenoid derivatives and pharmaceutical preparation containing same
|
US6166031A
(en)
|
1987-10-19 |
2000-12-26 |
Pfizer Inc, |
Substituted tetralins, chromans and related compounds in the treatment of asthma
|
US5059609A
(en)
|
1987-10-19 |
1991-10-22 |
Pfizer Inc. |
Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
|
CA1334975C
(en)
|
1987-11-13 |
1995-03-28 |
James H. Holms |
Furan and pyrrole containing lipoxygenase inhibiting compounds
|
JPH01149764A
(ja)
|
1987-12-07 |
1989-06-12 |
Green Cross Corp:The |
ビス−s−アルキルベンゼン誘導体
|
CA1331757C
(en)
|
1988-02-29 |
1994-08-30 |
Janssen Pharmaceutica Naamloze Vennootschap |
5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
|
US4943587A
(en)
|
1988-05-19 |
1990-07-24 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
|
US5112868A
(en)
|
1988-05-19 |
1992-05-12 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
|
US5232939A
(en)
|
1988-07-26 |
1993-08-03 |
Sankyo Company Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5354768A
(en)
|
1988-07-26 |
1994-10-11 |
Sankyo Company, Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5665752A
(en)
|
1988-07-26 |
1997-09-09 |
Sankyo Company, Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5260294A
(en)
|
1988-08-09 |
1993-11-09 |
Hoffman-La Roche Inc. |
Chromanes and their pharmaceutical compositions and methods
|
GB8819110D0
(en)
|
1988-08-11 |
1988-09-14 |
Norsk Hydro As |
Antihypertensive drug & method for production
|
IE63225B1
(en)
|
1988-09-13 |
1995-04-05 |
Efamol Holdings |
Use of fatty acids in the treatment of myalgic encephalomyelitis
|
GB2223943A
(en)
|
1988-10-21 |
1990-04-25 |
Tillotts Pharma Ag |
Oral disage forms of omega-3 polyunsaturated acids
|
US5066658A
(en)
|
1988-11-10 |
1991-11-19 |
Ortho Pharmaceutical Corporation |
Substituted hydroxyureas
|
US5256680A
(en)
|
1988-11-29 |
1993-10-26 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
|
US5155122A
(en)
|
1988-11-29 |
1992-10-13 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
|
US5068251A
(en)
|
1988-12-16 |
1991-11-26 |
Abbott Laboratories |
Lipoxygenase inhibiting compounds
|
US4935243A
(en)
|
1988-12-19 |
1990-06-19 |
Pharmacaps, Inc. |
Chewable, edible soft gelatin capsule
|
IL92620A0
(en)
|
1988-12-23 |
1990-08-31 |
Ici Pharma |
Cycloalkane derivatives
|
US5234950A
(en)
|
1988-12-23 |
1993-08-10 |
Imperial Chemical Industries Plc |
Tetrahydrofuran derivatives
|
US5229386A
(en)
|
1989-01-05 |
1993-07-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
|
US5145860A
(en)
|
1989-01-05 |
1992-09-08 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds and pharmaceutical composition comprising the same
|
US5217971A
(en)
|
1989-01-05 |
1993-06-08 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds and pharmaceutical composition comprising the same
|
JP2839276B2
(ja)
|
1989-01-23 |
1998-12-16 |
日本分光工業株式会社 |
超臨界流体抽出・分離方法及び装置
|
US5217977A
(en)
|
1989-02-28 |
1993-06-08 |
Imperial Chemical Industries Plc |
Heterocyclic cycloalkanes
|
GB8906369D0
(en)
|
1989-03-20 |
1989-05-04 |
Tisdale Michael J |
Eicosapentaenoic acid
|
US5457130A
(en)
|
1989-03-20 |
1995-10-10 |
Cancer Research Campaign Technology Limited |
Eicosapentaenoic acid used to treat cachexia
|
US5298512A
(en)
|
1989-04-07 |
1994-03-29 |
Pfizer Inc. |
Substituted chromans and their use in the treatment of asthma, arthritis and related diseases
|
WO1990012006A1
(en)
|
1989-04-07 |
1990-10-18 |
Pfizer Inc. |
Substituted 1-[3-(heteroarylmethoxy)phenyl]alkanols and related compounds in the treatment of asthma, arthritis and related diseases
|
US5300655A
(en)
|
1989-04-18 |
1994-04-05 |
Pfizer Inc. |
2-carboxy-thiophene derivatives
|
US5047554A
(en)
|
1989-04-18 |
1991-09-10 |
Pfizer Inc. |
3-substituted-2-oxindole derivatives
|
US5006549A
(en)
|
1989-05-24 |
1991-04-09 |
Merck & Co., Inc. |
Novel 7-aroyl-4-hydroxy-3-methyl-benzofurans as dual inhibitors of cyclooxygenase and 5-lipoxygenase
|
US4962119A
(en)
|
1989-06-09 |
1990-10-09 |
Warner-Lambert Company |
Triazole derivatives of fenamates as antiinflammatory agents
|
US5066668A
(en)
|
1989-06-09 |
1991-11-19 |
Warner-Lambert Co. |
Triazole derivatives of fenamates as antiinflammatory agents
|
US5384318A
(en)
|
1989-06-22 |
1995-01-24 |
Pfizer Inc. |
Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
|
EP0410661B1
(en)
|
1989-07-26 |
1994-06-15 |
Imperial Chemical Industries Plc |
Bicyclic derivatives
|
US4975457A
(en)
|
1989-09-25 |
1990-12-04 |
Merck & Co., Inc. |
Trans 2,3-disubstituted-2,3-dihydro-5-hydroxy-benzofurans as inhibitors of leukotriene biosynthesis
|
US4978679A
(en)
|
1989-09-25 |
1990-12-18 |
Merck & Co., Inc. |
6- and/or 7-substituted-1,2,3,4,4A,9B-hexahydro-8-hydroxydibenzofuran-3-ols as inhibitors of leukotriene biosynthesis
|
GB9018134D0
(en)
|
1989-09-29 |
1990-10-03 |
Ici Plc |
Heterocyclic derivatives
|
JPH03148217A
(ja)
|
1989-11-02 |
1991-06-25 |
Terumo Corp |
フエノキシプロピルアミン誘導体またはその塩ならびにこれらを含有する抗潰瘍剤
|
US5504108A
(en)
|
1990-01-12 |
1996-04-02 |
The Ohio State University Research Foundation |
Optically pure 4-aryl-2-hydroxytetronic acids
|
US5093356A
(en)
|
1990-01-16 |
1992-03-03 |
Merck Frosst Canada, Inc. |
Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
|
US5036067A
(en)
|
1990-03-14 |
1991-07-30 |
Merck & Co., Inc. |
Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
|
US5234937A
(en)
|
1990-03-27 |
1993-08-10 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxphenyl oxazolyl methanones and related compounds as antiinflammatory agents
|
US5234939A
(en)
|
1990-03-27 |
1993-08-10 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl imidazolyl methanones and related compounds as antiinflammatory agents
|
US5102897A
(en)
|
1990-03-27 |
1992-04-07 |
Warner-Lambert Company |
3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues
|
US5143928A
(en)
|
1990-03-27 |
1992-09-01 |
Warner-Lambert Company |
3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
|
US5086064A
(en)
|
1990-03-27 |
1992-02-04 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxazolyl, and imidazolyl methanones and related compounds as antiinflammatory agents
|
DK95490D0
(da)
|
1990-04-18 |
1990-04-18 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af triglycerid og triglyceridsammensaetning
|
WO1991016901A1
(en)
|
1990-04-30 |
1991-11-14 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide modulation of arachidonic acid metabolism
|
CA2043615C
(en)
|
1990-06-04 |
2001-08-14 |
Kazuhiko Hata |
Method of producing eicosapentaenoic acid or the ester derivative thereof
|
GB9012651D0
(en)
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
IE911853A1
(en)
|
1990-06-21 |
1992-01-01 |
Ici Plc |
Heterocyclene derivatives
|
AU637500B2
(en)
|
1990-06-21 |
1993-05-27 |
Zeneca Limited |
Bicyclic heterocyclic compounds
|
US5254581A
(en)
|
1990-06-21 |
1993-10-19 |
Imperial Chemical Industries Plc |
Pyran derivatives and their use as inhibitors of 5-lipoxygenase
|
US5064851A
(en)
|
1990-07-24 |
1991-11-12 |
Pfizer Inc. |
3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
|
PT98865A
(pt)
|
1990-09-07 |
1992-07-31 |
Searle & Co |
Processo para a preparacao de tioeter-amidas fenolicas
|
JPH04134077A
(ja)
|
1990-09-21 |
1992-05-07 |
Taiho Yakuhin Kogyo Kk |
イソオキサゾール化合物
|
US5811432A
(en)
|
1990-11-09 |
1998-09-22 |
Pfizer Inc |
Azaoxindole derivatives
|
JP3103588B2
(ja)
|
1990-11-16 |
2000-10-30 |
持田製薬株式会社 |
リポプロテイン(a)低下剤
|
US5248682A
(en)
|
1991-01-31 |
1993-09-28 |
Warner-Lambert Company |
2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
US5177079A
(en)
|
1991-01-31 |
1993-01-05 |
Warner-Lambert Company |
2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
EP0505122A1
(en)
|
1991-03-21 |
1992-09-23 |
Zeneca Limited |
Alpha, alpha-dialkylbenzyl derivatives
|
US5130485A
(en)
|
1991-04-23 |
1992-07-14 |
Eli Lilly And Company |
N-hydroxy-N-(3-(2-substituted phenyl)prop-2-enyl)ureas and thioureas useful as 5-lipoxygenase inhibiting agents
|
US5283361A
(en)
|
1991-04-23 |
1994-02-01 |
Eli Lilly And Company |
N-hydroxy-N-[3-[2-(halophenylthio)phenyl]prop-2-enyl]ureas as lipoxygenase inhibitors
|
US5147893A
(en)
|
1991-05-09 |
1992-09-15 |
G. D. Searle & Co. |
Cyclic phenolic thioethers
|
US5114958A
(en)
|
1991-05-09 |
1992-05-19 |
Warner-Lambert Company |
1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents
|
US5442111A
(en)
|
1991-05-24 |
1995-08-15 |
Warner-Lambert Company |
3,5-di-tetriary-4-butyl-4-hydroxyphenyloxy- or tioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas as 5-lipoxygenase inhibitors
|
SE9101642D0
(sv)
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
US5215630A
(en)
|
1991-06-04 |
1993-06-01 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
|
DE4123613C1
(ru)
|
1991-07-17 |
1993-02-04 |
Gruenenthal Gmbh, 5100 Aachen, De |
|
DE4124345A1
(de)
|
1991-07-23 |
1993-01-28 |
Gruenenthal Gmbh |
Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
|
AU2384292A
(en)
|
1991-07-30 |
1993-03-02 |
North Carolina State University |
Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
|
US5250547A
(en)
|
1991-08-29 |
1993-10-05 |
Syntex (U.S.A.) Inc. |
Benzopyran derivatives
|
US5270319A
(en)
|
1991-09-09 |
1993-12-14 |
Warner-Lambert Company |
5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
|
CA2076257A1
(en)
|
1991-09-13 |
1993-03-14 |
Jan Heeres |
4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives
|
DE4133694C2
(de)
|
1991-10-11 |
1993-10-07 |
Fresenius Ag |
Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
|
JP3400466B2
(ja)
|
1991-10-28 |
2003-04-28 |
日本水産株式会社 |
高純度エイコサペンタエン酸またはそのエステルの製造方法
|
WO1993009774A1
(en)
|
1991-11-18 |
1993-05-27 |
G.D. Searle & Co. |
2-(4-substituted)phenylmethylene derivatives and methods of use
|
US5476944A
(en)
|
1991-11-18 |
1995-12-19 |
G. D. Searle & Co. |
Derivatives of cyclic phenolic thioethers
|
US5212189A
(en)
|
1991-12-17 |
1993-05-18 |
Warner-Lambert Company |
Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
|
US5288896A
(en)
|
1992-01-15 |
1994-02-22 |
Warner-Lambert Company |
3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor
|
DE4204686A1
(de)
|
1992-02-17 |
1993-08-19 |
Gruenenthal Gmbh |
Imidazolylphenolderivate, diese enthaltende arzneimittel sowie ein verfahren zur herstellung dieser verbindungen und arzneimitteln
|
US5196431A
(en)
|
1992-02-24 |
1993-03-23 |
Warner-Lambert Company |
2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5220025A
(en)
|
1992-02-24 |
1993-06-15 |
Warner-Lambert Company |
2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5639782A
(en)
|
1992-03-04 |
1997-06-17 |
Center For Innovative Technology |
Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
|
US5530141A
(en)
|
1992-03-04 |
1996-06-25 |
Center For Innovative Technology |
2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5595872A
(en)
|
1992-03-06 |
1997-01-21 |
Bristol-Myers Squibb Company |
Nucleic acids encoding microsomal trigyceride transfer protein
|
US5187175A
(en)
|
1992-03-06 |
1993-02-16 |
Warner-Lambert Company |
2-carbonyl substituted-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5215986A
(en)
|
1992-06-01 |
1993-06-01 |
Warner-Lambert Company |
5-hydroxy-2-pyrimidinylmethylene oxaza heterocycles
|
US5208364A
(en)
|
1992-06-25 |
1993-05-04 |
Bristol-Myers Squibb Co. |
Antibiotic 5-lipoxygenase inhibitors
|
US5314898A
(en)
|
1992-06-29 |
1994-05-24 |
Merck & Co., Inc. |
Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
|
US5463083A
(en)
|
1992-07-13 |
1995-10-31 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
CA2140034A1
(en)
|
1992-07-13 |
1994-01-20 |
Xiong Cai |
2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
|
US5358938A
(en)
|
1992-07-13 |
1994-10-25 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5434151A
(en)
|
1992-08-24 |
1995-07-18 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5648486A
(en)
|
1992-07-13 |
1997-07-15 |
Cytomed, Inc. |
Compounds and methods for the treatment of inflammatory and immune disorders
|
US5541218A
(en)
|
1992-07-23 |
1996-07-30 |
Pfizer Inc. |
Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors
|
JPH0649479A
(ja)
|
1992-07-28 |
1994-02-22 |
Maruha Corp |
ω−3不飽和脂肪酸系化合物の安定化法
|
US5240929A
(en)
|
1992-08-03 |
1993-08-31 |
Warner-Lambert Company |
2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
GB9217780D0
(en)
|
1992-08-21 |
1992-10-07 |
Efamol Holdings |
Fatty acid treatment
|
US5888541A
(en)
|
1992-08-21 |
1999-03-30 |
Scotia Holdings Plc |
Fatty acid treatment
|
JPH0692847A
(ja)
|
1992-09-11 |
1994-04-05 |
Mochida Pharmaceut Co Ltd |
骨粗鬆症治療剤
|
WO1994010125A1
(en)
|
1992-10-27 |
1994-05-11 |
Sandoz Ltd. |
Glycerin derivatives and uses thereof
|
US5288751A
(en)
|
1992-11-06 |
1994-02-22 |
Abbott Laboratories |
[(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
|
US5314900A
(en)
|
1992-11-19 |
1994-05-24 |
Merck Frosst Canada, Inc. |
Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis
|
US5326907A
(en)
|
1992-12-18 |
1994-07-05 |
G. D. Searle & Co. |
2-aminoethanesulfonic acid derivatives of 3,5-disubstituted-4-hydroxyphenolic thioethers
|
US5292900A
(en)
|
1992-12-18 |
1994-03-08 |
Abbott Laboratories |
O-substituted N-hydroxyurea derivatives
|
GB9300125D0
(en)
|
1993-01-06 |
1993-03-03 |
Scotia Holdings Plc |
Compositions containing esters of unsaturated fatty acids
|
ES2062943B1
(es)
|
1993-03-23 |
1995-11-16 |
Uriach & Cia Sa J |
Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
|
IL109311A0
(en)
|
1993-04-16 |
1994-07-31 |
Lilly Co Eli |
1H-indole-3-acetamide sPla2 inhibitors
|
AP9400632A0
(en)
|
1993-04-29 |
1995-10-07 |
Zeneca Ltd |
Ether derivatives.
|
EP0697868A4
(en)
|
1993-05-10 |
1998-04-08 |
Sepracor Inc |
METHOD AND COMPOSITION USING OPTICALLY PURE (+) - ZILEUTON
|
US6239170B1
(en)
|
1993-05-28 |
2001-05-29 |
Gurpreet S. Ahluwalia |
Inhibition of hair growth
|
WO1994028891A1
(en)
|
1993-06-04 |
1994-12-22 |
Martek Biosciences Corporation |
Method of treating coronary vascular disease using docosahexaenoic acid
|
JPH0738598A
(ja)
|
1993-06-29 |
1995-02-07 |
Toshiba Corp |
ネットワークアダプタ群管理装置
|
US5739135A
(en)
|
1993-09-03 |
1998-04-14 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
GB9318611D0
(en)
|
1993-09-08 |
1993-10-27 |
Sandoz Nutrition Ltd |
Improvements in or relating to organic compounds
|
US5459154A
(en)
|
1993-11-08 |
1995-10-17 |
American Home Products Corporation |
N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein
|
ES2087019B1
(es)
|
1994-02-08 |
1997-03-16 |
Bobel246 S L |
Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
|
JP3325995B2
(ja)
|
1994-02-28 |
2002-09-17 |
ミサワホーム株式会社 |
パネル接合構造
|
GB9403857D0
(en)
|
1994-03-01 |
1994-04-20 |
Scotia Holdings Plc |
Fatty acid derivatives
|
GB9404483D0
(en)
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
MX9603943A
(es)
|
1994-03-09 |
1997-04-30 |
Pfizer |
Compuestos de isoxazolina como inhibidores de 5-lipooxigenasa.
|
US6252084B1
(en)
|
1994-03-15 |
2001-06-26 |
Eli Lilly And Company |
1H-indole-3-acetamide sPLA2 inhibitors
|
ES2119377T3
(es)
|
1994-03-28 |
1998-10-01 |
Pfizer |
Derivados bencisotiazoles inhibidores de la biosintesis de la 5-lipoxigenasa.
|
CN1067054C
(zh)
|
1994-04-01 |
2001-06-13 |
伊莱利利公司 |
1H-吲哚-3-乙醛酰胺sPLA2抑制剂
|
US5385929A
(en)
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
US5534524A
(en)
|
1994-05-09 |
1996-07-09 |
Board Of Regents, The University Of Texas System |
Suppression of bone resorption by quinolines
|
US5760081A
(en)
|
1994-05-10 |
1998-06-02 |
The General Hospital Corporation |
Omega 3 fatty acids in the prevention of ventricular fibrillation
|
JP3179286B2
(ja)
|
1994-05-19 |
2001-06-25 |
ファイザー製薬株式会社 |
N−ヒドロキシ尿素系抗炎症剤
|
JP3368100B2
(ja)
|
1994-06-02 |
2003-01-20 |
キヤノン株式会社 |
静電荷像現像用トナー
|
US5750565A
(en)
|
1995-05-25 |
1998-05-12 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5703093A
(en)
|
1995-05-31 |
1997-12-30 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5792776A
(en)
|
1994-06-27 |
1998-08-11 |
Cytomed, Inc., |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
AU711482B2
(en)
|
1994-06-28 |
1999-10-14 |
Scotia Holdings Plc |
Compositions for treatment of diabetic complications
|
US5641800A
(en)
|
1994-07-21 |
1997-06-24 |
Eli Lilly And Company |
1H-indole-1-functional sPLA2 inhibitors
|
US6214876B1
(en)
|
1994-07-21 |
2001-04-10 |
Eli Lilly And Company |
Indene-1-acetamide sPLA2 inhibitors
|
JPH0850637A
(ja)
|
1994-08-04 |
1996-02-20 |
Toshiba Corp |
帳票類取扱装置
|
IT1274734B
(it)
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
US5674488A
(en)
|
1994-10-07 |
1997-10-07 |
Reich; John J. |
Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
|
US5635514A
(en)
|
1994-10-25 |
1997-06-03 |
G. D. Searle & Company |
Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors
|
JPH08193074A
(ja)
|
1994-11-18 |
1996-07-30 |
Nippon Bayeragrochem Kk |
除草性1−シクロプロピルテトラゾリノン類
|
JPH08165267A
(ja)
|
1994-12-14 |
1996-06-25 |
Yakult Honsha Co Ltd |
ジアリルヘプタノイド誘導体およびこれを含有する抗炎症剤
|
JP2780154B2
(ja)
|
1995-02-17 |
1998-07-30 |
株式会社ヤクルト本社 |
ヨーグルト
|
US5514703A
(en)
|
1995-03-13 |
1996-05-07 |
Eli Lilly And Company |
Benzothiophene compounds useful for inhibiting lipoxygenase
|
JPH0840981A
(ja)
|
1995-03-24 |
1996-02-13 |
Nissui Pharm Co Ltd |
エイコサペンタエノイルグリセライド
|
US5516789A
(en)
|
1995-04-12 |
1996-05-14 |
Abbott Laboratories |
Lipoxygenase and cyclooxygenase inhibiting compounds
|
MY118354A
(en)
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
GB9509764D0
(en)
|
1995-05-15 |
1995-07-05 |
Tillotts Pharma Ag |
Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
|
EP0828718A1
(en)
|
1995-06-02 |
1998-03-18 |
G.D. SEARLE & CO. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6136839A
(en)
|
1995-06-12 |
2000-10-24 |
G. D. Searle & Co. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
|
JPH0959206A
(ja)
|
1995-08-25 |
1997-03-04 |
Nippon Oil & Fats Co Ltd |
エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
|
GB9519661D0
(en)
|
1995-09-27 |
1995-11-29 |
Scotia Holdings Plc |
Fatty acid treatment
|
JP3552810B2
(ja)
|
1995-09-27 |
2004-08-11 |
松下電器産業株式会社 |
部品供給部の部品一括交換方法と装置
|
EP0871713B1
(en)
|
1995-11-09 |
2007-02-14 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
|
US5763496A
(en)
|
1995-11-27 |
1998-06-09 |
The Research Foundation Of State University Of New York |
Prevention of atherosclerosis using NADPH oxidase inhibitors
|
US5762413A
(en)
|
1996-01-29 |
1998-06-09 |
Alternate Realities Corporation |
Tiltable hemispherical optical projection systems and methods having constant angular separation of projected pixels
|
US6231189B1
(en)
|
1996-01-29 |
2001-05-15 |
Elumens Corporation |
Dual polarization optical projection systems and methods
|
DE69709069T2
(de)
|
1996-02-13 |
2002-07-04 |
Searle & Co |
Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
|
WO1997039759A2
(en)
|
1996-04-24 |
1997-10-30 |
Brigham And Women's Hospital |
Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
|
US6077828A
(en)
|
1996-04-25 |
2000-06-20 |
Abbott Laboratories |
Method for the prevention and treatment of cachexia and anorexia
|
WO1997042347A2
(en)
|
1996-05-06 |
1997-11-13 |
Brigham And Women's Hospital |
5-lipoxygenase gene polymorphisms and their use in classifying patients
|
US6090547A
(en)
|
1997-04-25 |
2000-07-18 |
Brigham & Women's Hospital |
Identification of asthma patients who are candidates for effective treatment with 5-lipoxygenase inhibitors
|
US5827875A
(en)
|
1996-05-10 |
1998-10-27 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US5885983A
(en)
|
1996-05-10 |
1999-03-23 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US6248398B1
(en)
|
1996-05-22 |
2001-06-19 |
Applied Materials, Inc. |
Coater having a controllable pressurized process chamber for semiconductor processing
|
US6776986B1
(en)
|
1996-06-06 |
2004-08-17 |
Novartis Ag |
Inhibition of HIV-1 replication by antisense RNA expression
|
TW425285B
(en)
|
1996-06-10 |
2001-03-11 |
Viva America Marketing Inc |
Fish oil and garlic nutritive supplement
|
US5965619A
(en)
|
1996-06-13 |
1999-10-12 |
Cell Pathways Inc. |
Method for treating patients having precancerous lesions with substituted indene derivatives
|
US6121321A
(en)
|
1996-06-13 |
2000-09-19 |
Cell Pathways, Inc. |
Substituted methoxy benzylidene indenyl acetic and propionic acids for treating patients with precancerous lesions
|
US5998477A
(en)
|
1996-06-13 |
1999-12-07 |
Cell Pathways Inc. |
Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
|
US6063818A
(en)
|
1996-06-13 |
2000-05-16 |
Cell Pathways Inc. |
Substituted benzylidene indenyl formamides, acetamides and propionamides
|
US5861399A
(en)
|
1996-07-17 |
1999-01-19 |
Heart Care Partners |
Methods and compositions for the rapid and enduring relief of inadequate myocardial function
|
US6005000A
(en)
|
1996-08-22 |
1999-12-21 |
Oxis International, Inc. |
5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
|
DE19636150A1
(de)
|
1996-09-06 |
1998-03-12 |
Asta Medica Ag |
N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
|
US20020055539A1
(en)
|
1996-10-02 |
2002-05-09 |
Bockow Barry I. |
Compositions and methods for treating cardiovascular conditions
|
NZ334852A
(en)
|
1996-10-11 |
2001-05-25 |
Scotia Holdings Plc |
Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
|
US6426335B1
(en)
|
1997-10-17 |
2002-07-30 |
Gilead Sciences, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
US6569539B2
(en)
|
1996-10-30 |
2003-05-27 |
Tetra Level Holdings & Finance S.A. |
Gas barrier packaging laminate method for production thereof and packaging containers
|
US6713645B1
(en)
|
1996-10-30 |
2004-03-30 |
Eli Lilly And Company |
Substituted tricyclics
|
US6177440B1
(en)
|
1996-10-30 |
2001-01-23 |
Eli Lilly And Company |
Substituted tricyclics
|
JP4176166B2
(ja)
*
|
1996-11-15 |
2008-11-05 |
持田製薬株式会社 |
横紋筋融解症治療剤
|
DE69622722T2
(de)
|
1996-11-20 |
2003-02-27 |
Nutricia Nv |
Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
|
US5909734A
(en)
|
1996-12-03 |
1999-06-08 |
Regents Of The University Of Michigan |
Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
|
US5916922A
(en)
|
1996-12-03 |
1999-06-29 |
Eli Lilly And Company |
Phenyl glyoxamides as SPLA2 inhibitors
|
US6353128B1
(en)
|
1996-12-03 |
2002-03-05 |
Eli Lilly And Company |
Phenyl acetamides as sPLA2 inhibitors
|
ID18983A
(id)
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
US6011049A
(en)
|
1997-02-19 |
2000-01-04 |
Warner-Lambert Company |
Combinations for diabetes
|
TR199902579T2
(xx)
|
1997-04-18 |
2000-01-21 |
Pfizer Inc. |
4'-Triflorometil-Bifenil-2-Karboksilik asit (1,2,3,4-Tetrahidro-Izokinolin-6-�l)-Amid' in haz�rlanmas� i�in y�ntem ve ara�lar
|
US6177415B1
(en)
|
1997-04-21 |
2001-01-23 |
The United States Of America As Represented By The Secretary Of Agriculture |
Bacteriohopanetetrol and related compounds useful for modulation of lipoxygenase activity and anti-inflammatory applications
|
JP4231559B2
(ja)
|
1997-04-23 |
2009-03-04 |
オリザ油化株式会社 |
リポキシゲナーゼ阻害剤
|
WO1998047507A1
(en)
|
1997-04-24 |
1998-10-29 |
Shionogi & Co., Ltd. |
Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
|
US20060025348A1
(en)
|
1997-05-28 |
2006-02-02 |
Pilon Aprile L |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20020169108A1
(en)
|
1997-05-28 |
2002-11-14 |
Pilon Aprile L. |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20030008816A1
(en)
|
1997-05-28 |
2003-01-09 |
Pilon Aprile L. |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
JP2001513555A
(ja)
|
1997-08-28 |
2001-09-04 |
イーライ・リリー・アンド・カンパニー |
非リウマチ様関節炎の処置方法
|
IT1304595B1
(it)
|
1997-08-29 |
2001-03-19 |
Giorgio Endrici |
Inibitore della 5-lipoossigenasi
|
JPH1180083A
(ja)
|
1997-09-10 |
1999-03-23 |
Nof Corp |
エイコサペンタエン酸エステルの製造方法
|
US6218524B1
(en)
|
1997-09-16 |
2001-04-17 |
Eurona Medical Ab |
Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof
|
US6177426B1
(en)
|
1997-10-27 |
2001-01-23 |
Eli Lilly And Company |
Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors
|
US6440961B1
(en)
|
1997-10-27 |
2002-08-27 |
Dr. Reddy's Research Foundation |
Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
|
WO1999021546A1
(en)
|
1997-10-27 |
1999-05-06 |
Eli Lilly And Company |
N,N-DIETHYLGLYCOLAMIDO ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
|
WO1999022719A1
(fr)
|
1997-10-30 |
1999-05-14 |
Morishita Jintan Co., Ltd. |
Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
|
WO1999025340A1
(en)
|
1997-11-14 |
1999-05-27 |
Eli Lilly And Company |
Treatment for alzheimer's disease
|
CA2310249A1
(en)
|
1997-11-14 |
1999-05-27 |
August Masaru Watanabe |
Treatment for alzheimer's disease
|
CN1160068C
(zh)
|
1997-11-25 |
2004-08-04 |
沃尼尔·朗伯公司 |
脂蛋白氧化的抑制剂
|
US6121323A
(en)
|
1997-12-03 |
2000-09-19 |
3M Innovative Properties Company |
Bishydroxyureas
|
EP1039893B1
(en)
|
1997-12-10 |
2011-02-02 |
Cyclosporine Therapeutics Limited |
Pharmaceutical compositions containing an omega-3 fatty acid oil
|
US5948779A
(en)
|
1997-12-12 |
1999-09-07 |
Cell Pathways, Inc. |
Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
|
US6916841B2
(en)
|
1998-02-25 |
2005-07-12 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
US6166062A
(en)
|
1998-03-03 |
2000-12-26 |
Shionogi & Co., Ltd. |
Pharmaceutical compositions containing phospholipase inhibitor
|
ATE269861T1
(de)
|
1998-03-31 |
2004-07-15 |
Inst For Pharm Discovery Inc |
Substituierte indolalkansäure
|
KR20010042307A
(ko)
|
1998-03-31 |
2001-05-25 |
시오노 요시히코 |
피롤로[1,2-a]피라진 sPLA2 억제제
|
US6028116A
(en)
|
1998-04-03 |
2000-02-22 |
Cell Pathways, Inc. |
Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
|
DZ2770A1
(fr)
|
1998-04-17 |
2003-12-01 |
Lilly Co Eli |
Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
|
US6407261B1
(en)
|
1998-04-17 |
2002-06-18 |
Eli Lilly And Company |
Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
|
CZ20004052A3
(cs)
|
1998-05-01 |
2002-05-15 |
Eli Lilly And Company |
Léčivo pro terapeutickou léčbu zánětlivého onemocnění střeva a prostředek pro tuto léčbu obsahující 1H-indol-3-glyoxylamid
|
EP1085021A4
(en)
|
1998-05-21 |
2003-01-08 |
Shionogi & Co |
DERIVATIVES OF PYRROLO 1,2-B] PYRIDAZINE, WITH INHIBITOR EFFECT ON SPLA 2?
|
AU4543899A
(en)
|
1998-06-08 |
1999-12-30 |
Advanced Medicine, Inc. |
Multibinding inhibitors of microsomal triglyceride transferase protein
|
US20020045271A1
(en)
|
1998-06-10 |
2002-04-18 |
Licata And Tyrrell P.C. |
Compounds and methods for identifying compounds that interact with microsomal triglyceride transfer protein binding sites on apolipoprotein b and modulate lipid biosynthesis
|
AU4710699A
(en)
|
1998-06-30 |
2000-01-17 |
Eli Lilly And Company |
Bicyclic sPLA2 inhibitors
|
DE19830375A1
(de)
|
1998-07-08 |
2000-01-13 |
K D Pharma Bexbach Gmbh |
Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
|
WO2000007590A1
(en)
|
1998-08-03 |
2000-02-17 |
Eli Lilly And Company |
INDOLE sPLA2 INHIBITORS
|
EP1100493A4
(en)
|
1998-08-03 |
2001-10-24 |
Lilly Co Eli |
SPLA 2 INHIBITORS? OF THE INDOLTYPS
|
US6576654B1
(en)
|
1998-09-23 |
2003-06-10 |
Eli Lilly And Company |
Method for the treatment of cystic fibrosis
|
US6221880B1
(en)
|
1998-10-09 |
2001-04-24 |
Schering Corporation |
Composition and method for treating allergic diseases
|
ATE329619T1
(de)
|
1998-10-14 |
2006-07-15 |
Shionogi & Co |
Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
|
US20030008914A1
(en)
|
1998-10-16 |
2003-01-09 |
C. Grace Yeh |
Pharmaceutical formulations useful to treat inflammatory and immune disorders
|
US6248553B1
(en)
|
1998-10-22 |
2001-06-19 |
Atairgin Technologies, Inc. |
Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
|
NZ500703A
(en)
|
1998-11-04 |
2001-06-29 |
F |
Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
US20020055529A1
(en)
|
1998-12-02 |
2002-05-09 |
Bisgaier Charles Larry |
Method for treating alzheimer's disease
|
DE69933471T2
(de)
|
1998-12-17 |
2007-08-30 |
Xenogen Corp., Alameda |
Unblutige bestimmung einer physiologischen reaktion in einem säugetier
|
US6448284B1
(en)
|
1998-12-22 |
2002-09-10 |
Eli Lilly And Company |
Substituted tricyclics
|
AU2373600A
(en)
|
1998-12-22 |
2000-07-12 |
Eli Lilly And Company |
Novel spla2 inhibitors
|
US6194585B1
(en)
|
1998-12-22 |
2001-02-27 |
Pfizer Inc. |
Process for preparing 5-lipoxygenase inhibitors
|
WO2000038725A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations for cardiovascular indications
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
CA2260397A1
(en)
|
1999-01-29 |
2000-07-29 |
Atlantis Marine Inc. |
Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
US6193999B1
(en)
|
1999-03-01 |
2001-02-27 |
Banner Pharmacaps, Inc. |
Gum acacia substituted soft gelatin capsules
|
CA2366318A1
(en)
|
1999-03-03 |
2000-09-08 |
Ida Royalty Aps |
Novel pharmaceutical, dietary and cosmetic compositions comprising zinger officinale roscoe, eicosapentaenoic acid and/or docosahexaenoic acid
|
US6596766B1
(en)
|
1999-03-04 |
2003-07-22 |
Suntory Limited |
Utilization of material containing docosapentaenoic acid
|
US20020110523A1
(en)
|
1999-03-23 |
2002-08-15 |
Cornelis Kluft |
Methods for screening or monitoring the risk of cardiovascular disease relating to sex steroid compound or composition intake and methods for screening sex steroid compound
|
US20020054871A1
(en)
|
1999-04-12 |
2002-05-09 |
Yadong Huang |
Methods and compositions for use in the treatment of hyperlipidemia
|
US6380397B1
(en)
|
1999-04-15 |
2002-04-30 |
Eli Lilly And Company |
Process for preparing 4-substituted-1H-indole-3-glyoxamides
|
US6274578B1
(en)
|
1999-04-20 |
2001-08-14 |
Eli Lilly And Company |
sPLA2 inhibitor ester
|
JP2001025519A
(ja)
|
1999-05-11 |
2001-01-30 |
Mamiya Op Co Ltd |
ゴルフクラブ用シャフト
|
US6140327A
(en)
|
1999-05-12 |
2000-10-31 |
Eli Lilly And Company |
Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
|
US7112609B2
(en)
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
US6207699B1
(en)
|
1999-06-18 |
2001-03-27 |
Richard Brian Rothman |
Pharmaceutical combinations for treating obesity and food craving
|
CA2311974A1
(en)
|
1999-06-28 |
2000-12-28 |
Nisshin Flour Milling Co., Ltd. |
Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
|
GB9916536D0
(en)
*
|
1999-07-14 |
1999-09-15 |
Scarista Limited |
Nutritional or pharmaceutical compositions
|
AU6015600A
(en)
|
1999-07-19 |
2001-02-05 |
Shionogi & Co., Ltd. |
Tricyclic compounds having spla2-inhibitory activities
|
US6706752B1
(en)
|
1999-07-19 |
2004-03-16 |
Eli Lilly And Company |
sPLA2 inhibitors
|
DE19933926A1
(de)
|
1999-07-20 |
2001-01-25 |
Boehringer Ingelheim Pharma |
Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
|
PT1072198E
(pt)
|
1999-07-28 |
2008-06-17 |
Swiss Caps Rechte & Lizenzen |
Preparado, especialmente para utilização como medicamento e/ou como suplemento alimentar
|
JP4636522B2
(ja)
|
1999-08-02 |
2011-02-23 |
塩野義製薬株式会社 |
sPLA2阻害作用を有する三環式化合物
|
AU6762400A
(en)
|
1999-08-12 |
2001-03-13 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
WO2001014378A1
(fr)
|
1999-08-23 |
2001-03-01 |
Shionogi & Co., Ltd. |
DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
|
EP1211955A1
(en)
|
1999-08-30 |
2002-06-12 |
Ocean Nutrition Canada Ltd. |
A nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US6344563B1
(en)
|
1999-08-31 |
2002-02-05 |
Timothy Norris |
Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
|
US6831095B1
(en)
|
1999-09-20 |
2004-12-14 |
Eli Lilly And Company |
Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
|
CA2385406A1
(en)
|
1999-09-21 |
2001-03-29 |
Shionogi & Co., Ltd. |
Gene encoding novel human secretory phospholipase a2
|
EP1220836A2
(en)
|
1999-10-15 |
2002-07-10 |
Bristol-Myers Squibb Pharma Company |
Benzylcycloalkyl amines as modulators of chemokine receptor activity
|
US6261607B1
(en)
|
1999-10-19 |
2001-07-17 |
Thomas Newmark |
Composition for promoting prostate health containing selenium and herbal extracts
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
CA2325358C
(en)
|
1999-11-10 |
2005-08-02 |
Pfizer Products Inc. |
7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
|
WO2001036420A1
(fr)
|
1999-11-15 |
2001-05-25 |
Shionogi & Co., Ltd. |
Derives d'aza-indolizine tricyclique ayant un effet inhibiteur sur spla¿2?
|
JP4170542B2
(ja)
|
1999-11-18 |
2008-10-22 |
日油株式会社 |
高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
|
DE19962300A1
(de)
|
1999-12-23 |
2001-06-28 |
Asta Medica Ag |
Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
|
ES2240420T3
(es)
|
2000-01-18 |
2005-10-16 |
Novartis Ag |
Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b.
|
EP1125914A1
(en)
|
2000-02-14 |
2001-08-22 |
Nisshin Flour Milling Co., Ltd. |
Process for separating and purifying eicosapentaenoic acid or its ester
|
DE10007203A1
(de)
|
2000-02-17 |
2001-08-23 |
Asta Medica Ag |
Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
|
SE0000754D0
(sv)
|
2000-03-07 |
2000-03-07 |
Amersham Pharm Biotech Ab |
Mass spectral peak identification
|
BR0109336A
(pt)
|
2000-03-17 |
2003-06-24 |
Ajinomoto C0 Inc |
Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
|
US7387797B2
(en)
|
2000-03-22 |
2008-06-17 |
Creighton University |
Compositions derived from Modiolus modiolus and methods for making and using same
|
EP1276906A2
(en)
|
2000-04-17 |
2003-01-22 |
Glaxo Group Limited |
Medicine response assay in respiratory disease
|
WO2001083440A2
(en)
|
2000-04-28 |
2001-11-08 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of thienotriazolodiazepines
|
DE10022925A1
(de)
|
2000-05-11 |
2001-11-15 |
Basf Ag |
Substituierte Indole als PARP-Inhibitoren
|
ATE305810T1
(de)
|
2000-05-22 |
2005-10-15 |
Pro Aparts Investimentos E Con |
Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
|
GB0013378D0
(en)
|
2000-06-01 |
2000-07-26 |
Glaxo Group Ltd |
Use of therapeutic benzamide derivatives
|
US6620821B2
(en)
|
2000-06-15 |
2003-09-16 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
DE10030375A1
(de)
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
AU2001268051A1
(en)
|
2000-06-28 |
2002-01-08 |
Eli Lilly And Company |
Spla2 inhibitors
|
US6967200B2
(en)
|
2000-06-29 |
2005-11-22 |
Shionogi & Co., Ltd. |
Remedies for cirrhosis
|
AU2001267823A1
(en)
|
2000-06-29 |
2002-01-08 |
Shionogi And Co., Ltd. |
Compounds exhibiting x-type spla2 inhibiting effect
|
US20040102442A1
(en)
|
2000-06-29 |
2004-05-27 |
Kohji Hanasaki |
Remedies for alzheimer's disease
|
AU2001267824A1
(en)
|
2000-06-29 |
2002-01-08 |
Shionogi And Co., Ltd. |
Remedies for cancer
|
GB0016045D0
(en)
|
2000-06-29 |
2000-08-23 |
Laxdale Limited |
Therapeutic combinations of fatty acids
|
GB0016452D0
(en)
|
2000-07-04 |
2000-08-23 |
Kilgowan Limited |
Vitamin K and essential fatty acids
|
US20020032238A1
(en)
|
2000-07-08 |
2002-03-14 |
Henning Priepke |
Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
|
WO2002008189A1
(en)
|
2000-07-24 |
2002-01-31 |
The University Of Queensland |
Compounds and inhibitors of phospholipases
|
WO2002011723A1
(en)
|
2000-08-04 |
2002-02-14 |
Mason R Preston |
Synergistic effect of amlodipine and atorvastatin
|
JP4391673B2
(ja)
|
2000-08-08 |
2009-12-24 |
花王株式会社 |
油脂組成物
|
US6417367B1
(en)
|
2000-08-11 |
2002-07-09 |
Pfizer Inc. |
Methods of making quinoline amides
|
AU2001284876A1
(en)
|
2000-08-15 |
2002-02-25 |
South Alabama Medical Science Foundation |
Treating sickle cell disease
|
MXPA03001419A
(es)
|
2000-08-15 |
2003-06-06 |
Pfizer Prod Inc |
Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
|
US6383482B1
(en)
|
2000-08-24 |
2002-05-07 |
Vitacost.Com, Inc. |
Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
|
US20120237626A9
(en)
|
2000-12-05 |
2012-09-20 |
Palu Afa Kehaati |
Profiles of lipid proteins and inhibiting HMG-CoA reductase
|
EP1349834A2
(en)
|
2000-12-18 |
2003-10-08 |
Eli Lilly And Company |
Cycloalkyfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
|
US6872743B2
(en)
|
2000-12-18 |
2005-03-29 |
Eli Lilly And Company |
sPLA2 inhibitors
|
CA2431506A1
(en)
|
2000-12-18 |
2002-07-25 |
Eli Lilly And Company |
Benz(g) indoles and their use as spla2 inhibitors
|
US6930123B2
(en)
|
2000-12-18 |
2005-08-16 |
Eli Lilly And Company |
sPLA2 inhibitors
|
GB0101198D0
(en)
|
2001-01-17 |
2001-02-28 |
Scherer Technologies Inc R P |
Ingestible compositions containing an odoriferous oil
|
WO2002057795A2
(en)
|
2001-01-19 |
2002-07-25 |
Cambridge Scientific, Inc. |
Methods of diagnosis and treatment of osteoporosis
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
AU2002240286A1
(en)
|
2001-02-08 |
2002-08-19 |
Millennium Pharmaceuticals, Inc. |
Detection of polymorphisms in the human 5-lipoxygenase gene
|
TWI314457B
(ru)
|
2001-03-19 |
2009-09-11 |
Shionogi & Co |
|
ATE353876T1
(de)
|
2001-03-28 |
2007-03-15 |
Lilly Co Eli |
Substituierte carbazole als inhibitoren von spla2
|
US7524635B2
(en)
|
2003-04-17 |
2009-04-28 |
Biosite Incorporated |
Methods and compositions for measuring natriuretic peptides and uses thereof
|
GB0111282D0
(en)
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
IL143379A
(en)
|
2001-05-24 |
2013-11-28 |
Yissum Res Dev Co |
Oligonucleotide against human ache isoform r and its uses
|
CN1268328C
(zh)
|
2001-05-30 |
2006-08-09 |
拉克斯戴尔有限公司 |
辅酶q与二十碳五烯酸(epa)
|
US7901713B2
(en)
|
2001-06-20 |
2011-03-08 |
Metaproteomics, Llc |
Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
|
US6756399B2
(en)
|
2001-06-29 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
|
US6730694B1
(en)
|
2001-07-20 |
2004-05-04 |
Eli Lilly And Company |
sPLA2 inhibitors
|
US20120214771A1
(en)
|
2001-07-27 |
2012-08-23 |
Fontini Sampalis |
Compositions for treatment of cardiometabolic disorders
|
US7109231B2
(en)
|
2001-08-09 |
2006-09-19 |
Eli Lilly And Company |
Cyclohept[b]indole derivatives
|
EP1423366A1
(en)
|
2001-08-09 |
2004-06-02 |
Eli Lilly And Company |
Cyclopenta b ! indole derivatives as spla2 inhibitors
|
BR0212794A
(pt)
|
2001-09-13 |
2004-10-05 |
Synta Pharmaceuticals Corp |
Composto de 1-glioxililamida indolizina e seu uso
|
JP2005504790A
(ja)
|
2001-09-13 |
2005-02-17 |
シンタ ファーマスーティカルズ コーポレイション |
癌を治療するための3−グリオキシリルアミドインドール
|
ITMI20012384A1
(it)
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
AU2002352726A1
(en)
|
2001-11-15 |
2003-06-10 |
Galileo Laboratories, Inc. |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
US20040018248A1
(en)
|
2001-11-29 |
2004-01-29 |
Adrianne Bendich |
Composition containing statins and calcium for improved cardiovascular health
|
AU2002364900A1
(en)
|
2001-11-30 |
2003-06-17 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
|
US6635771B2
(en)
|
2001-12-03 |
2003-10-21 |
Wyeth |
N-benzhydryl indole compounds
|
US6984735B2
(en)
|
2001-12-03 |
2006-01-10 |
Wyeth |
Process for making an aldehyde
|
US6797708B2
(en)
|
2001-12-03 |
2004-09-28 |
Wyeth |
Inhibitors of cytosolic phospholipase A2
|
US7101875B2
(en)
|
2001-12-03 |
2006-09-05 |
Wyeth |
Methods for treating arthritic disorders
|
US6992100B2
(en)
|
2001-12-06 |
2006-01-31 |
Eli Lilly And Company |
sPLA2 inhibitors
|
US6903104B2
(en)
|
2001-12-06 |
2005-06-07 |
National Health Research Institutes |
Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
|
ITMI20020269A1
(it)
|
2002-02-12 |
2003-08-12 |
Victorix Assets Ltd |
Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
|
JP2003306690A
(ja)
|
2002-02-18 |
2003-10-31 |
Nooburu:Kk |
多価不飽和脂肪酸含有油脂組成物
|
HUP0200686A2
(hu)
|
2002-02-22 |
2003-09-29 |
EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. |
Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
|
US20030166614A1
(en)
|
2002-03-01 |
2003-09-04 |
Harrison Stanley F. |
Method for reducing cholesterol and triglycerides
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
WO2003092599A2
(en)
|
2002-04-30 |
2003-11-13 |
Unigen Pharmaceuticals, Inc. |
Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
|
EP1501493B1
(en)
|
2002-05-03 |
2009-10-07 |
Pronova BioPharma Norge AS |
Use of epa and dha in secondary prevention of strokes
|
AU2003240536B2
(en)
|
2002-06-05 |
2007-11-15 |
Ivax Pharmaceuticals, S.R.O. |
Reduction of gelatin cross-linking
|
US20030092767A1
(en)
|
2002-06-07 |
2003-05-15 |
Macias William Louis |
Combination therapy for the treatment of inflammatory and respiratory diseases
|
CA2390820A1
(en)
|
2002-06-17 |
2003-12-17 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
US20040077691A1
(en)
|
2002-06-21 |
2004-04-22 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
US6620813B1
(en)
|
2002-06-21 |
2003-09-16 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
US20040001874A1
(en)
|
2002-06-24 |
2004-01-01 |
Vital Living, Inc. |
Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
|
US6653311B1
(en)
|
2002-06-25 |
2003-11-25 |
Board Of Supervisors Of Louisiana State University |
5-lipoxygenase inhibitors: (2-azinylamino) quinone derivatives
|
US20040048919A1
(en)
|
2002-07-02 |
2004-03-11 |
Dreon Darlene M. |
Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
|
US20060211761A1
(en)
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
US20030087944A1
(en)
|
2002-08-05 |
2003-05-08 |
Macias William Louis |
Method for the treatment of renal dysfunction with spla2 inhibitors
|
US7314643B2
(en)
|
2002-08-20 |
2008-01-01 |
Nikken Chemicals Co., Ltd. |
Soft capsule preparation
|
DE20214847U1
(de)
|
2002-09-24 |
2004-02-19 |
Voss Automotive Gmbh |
Anschlußvorrichtung für Rohrleitungen
|
KR100539027B1
(ko)
|
2002-10-18 |
2005-12-26 |
현대모비스 주식회사 |
차량의 조향각 검출 장치
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US7528112B2
(en)
|
2002-11-15 |
2009-05-05 |
Drexel University |
Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
|
US8106019B2
(en)
|
2002-11-15 |
2012-01-31 |
Philadelphia Health & Education Corporation |
CHEC-7 a novel sPLA2 inhibitor
|
US8017651B2
(en)
|
2002-11-22 |
2011-09-13 |
Bionexus, Ltd. |
Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
|
KR101045035B1
(ko)
|
2002-11-22 |
2011-06-30 |
니폰스이산가부시키가이샤 |
산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는조성물
|
ITMI20022511A1
(it)
*
|
2002-11-26 |
2004-05-27 |
Victorix Assets Ltd |
Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
|
GB0228079D0
(en)
|
2002-12-02 |
2003-01-08 |
Laxdale Ltd |
Huntington's Disease
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
US20040198800A1
(en)
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
WO2004056777A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Microsomal triglyceride transfer protein inhibitors
|
JP2006516028A
(ja)
|
2002-12-20 |
2006-06-15 |
ファイザー・プロダクツ・インク |
ミクロソームトリグリセリド輸送タンパク質阻害剤
|
EP1589930A2
(en)
|
2003-01-08 |
2005-11-02 |
Flacco-Nesselroad Family Trust |
Combination therapy for anticoagulation
|
ES2291729T7
(es)
|
2003-01-09 |
2010-03-31 |
Astellas Pharma Inc. |
Derivados de pirrolopiridazina.
|
GB0301701D0
(en)
|
2003-01-24 |
2003-02-26 |
Ensay Ltd |
Psoriasis and Eicosapentaenoic acid
|
EP1587377A2
(en)
|
2003-01-31 |
2005-10-26 |
The Procter & Gamble Company |
Means for improving the appearance of mammalian keratinous tissue
|
CA2515293C
(en)
|
2003-02-07 |
2012-03-20 |
Mochida Pharmaceutical Co., Ltd. |
Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
|
WO2004073623A2
(en)
|
2003-02-14 |
2004-09-02 |
Children's Hospital & Research Center At Oakland |
Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
|
EP1595539A4
(en)
|
2003-02-21 |
2007-04-11 |
Mochida Pharm Co Ltd |
DRUGS TO REDUCE THE SIDE EFFECTS OF RIBAVIRIN INTERFERON COMBINATION THERAPY
|
AU2004216856A1
(en)
|
2003-03-05 |
2004-09-16 |
Solvay Pharmaceuticals Gmbh |
Use of omega-3-fatty acids in the treatment of diabetic patients
|
EP1605781A1
(en)
*
|
2003-03-18 |
2005-12-21 |
Novartis AG |
Compositions comprising fatty acids and amino acids
|
US20050090426A1
(en)
|
2003-03-24 |
2005-04-28 |
Blumberg Richard S. |
Methods of inhibiting inflammation
|
US20050234073A1
(en)
|
2003-03-24 |
2005-10-20 |
Blumberg Richard S |
Methods of inhibiting inflammation
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
US7329682B2
(en)
|
2003-04-03 |
2008-02-12 |
Ewha University-Industry Collaboration Foundation |
Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
|
US20070066577A1
(en)
|
2003-04-03 |
2007-03-22 |
Hea Young Park Choo |
Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7579433B2
(en)
|
2003-04-30 |
2009-08-25 |
National University Of Singapore |
Methods and compositions for treatment of arthritis and cancer
|
US7176281B2
(en)
|
2003-04-30 |
2007-02-13 |
National University Of Singapore |
Phospholipase A2-inhibitory peptide with anti-arthritic and neuroprotective activities
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
US6846942B2
(en)
|
2003-05-20 |
2005-01-25 |
David Rubin |
Method for preparing pure EPA and pure DHA
|
US20040235807A1
(en)
|
2003-05-21 |
2004-11-25 |
Weinrich Karl P. |
Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
|
US7205329B2
(en)
|
2003-05-30 |
2007-04-17 |
Microbia, Inc. |
Modulators of CRTH2 activity
|
EP1637134A4
(en)
|
2003-06-20 |
2010-01-27 |
Mochida Pharm Co Ltd |
COMPOSITION FOR THE PREVENTION AND TREATMENT OF VARICES
|
WO2005020785A2
(en)
|
2003-07-15 |
2005-03-10 |
The Regents Of The University Of California |
Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
|
KR20130023381A
(ko)
|
2003-07-17 |
2013-03-07 |
플렉시콘, 인코퍼레이티드 |
Ppar 활성 화합물
|
ATE457166T1
(de)
|
2003-07-24 |
2010-02-15 |
Wockhardt Ltd |
Orale zusammensetzungen zur behandlung von diabetes
|
CN100443487C
(zh)
|
2003-07-31 |
2008-12-17 |
惠氏公司 |
作为5-羟色胺-6配位体的n-磺酰基杂环吡咯基烷基胺化合物
|
EP1653969A4
(en)
|
2003-08-07 |
2006-12-20 |
Japan Tobacco Inc |
PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
|
WO2005018436A2
(en)
|
2003-08-26 |
2005-03-03 |
The Trustees Of Boston University |
Methods for the diagnosis, prognosis and treatment of metabolic syndrome
|
JP2007505862A
(ja)
|
2003-09-22 |
2007-03-15 |
バイオスペシフィク ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
sPLA2の効果の失効方法
|
IL158600A
(en)
|
2003-10-26 |
2015-07-30 |
Hermona Soreq |
Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
|
WO2005047479A2
(en)
|
2003-11-12 |
2005-05-26 |
E.I. Dupont De Nemours And Company |
Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast
|
ITMI20032247A1
(it)
|
2003-11-19 |
2005-05-20 |
Tiberio Bruzzese |
Interazione di derivati polari di composti insaturi con substrati inorganici
|
SE0303513D0
(sv)
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
GB2409644B
(en)
|
2003-12-31 |
2005-12-21 |
Igennus Ltd |
Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
|
IL159729A0
(en)
|
2004-01-06 |
2004-06-20 |
Doron I Friedman |
Non-aqueous composition for oral delivery of insoluble bioactive agents
|
GB0403247D0
(en)
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
US7022713B2
(en)
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
EP1591114A1
(en)
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Use of metformin and orlistat for the treatment or prevention of obesity
|
US20050215640A1
(en)
|
2004-03-26 |
2005-09-29 |
Baxter Jeffrey H |
HMB compositions and uses thereof
|
US7923043B2
(en)
|
2004-03-30 |
2011-04-12 |
Theta Biomedical Consulting & Development Co., Inc. |
Method for protecting humans against superficial vasodilator flush syndrome
|
US20050244367A1
(en)
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
US20050272095A1
(en)
|
2004-05-19 |
2005-12-08 |
Ppd Biomarker Discovery Sciences, Llc |
Methods of identifying biomarkers
|
US20050267145A1
(en)
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
TW200613009A
(en)
|
2004-06-11 |
2006-05-01 |
Ono Pharmaceutical Co |
Capsule having chewing stability
|
GB0413730D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
GB0413729D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
ES2399726T3
(es)
|
2004-07-16 |
2013-04-03 |
I.N.S.E.R.M. Institut National De La Santé Et De La Recherche Medicale |
La fosfolipasa A2 (sPLA2) secretora como marcador pronóstico y diagnóstico para enfermedades cardiovasculares
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
MX2007001155A
(es)
|
2004-07-29 |
2007-08-14 |
Creabilis Therapeutics Spa |
Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
|
US20070231345A1
(en)
|
2004-08-02 |
2007-10-04 |
Muhammed Majeed |
Medicament containing natural leucotriene inhibitors singly or in combination with bioavailable organic selenium supplement for hyperproliferative dermatological conditions and therapeutic methods thereof
|
ITRM20040395A1
(it)
*
|
2004-08-03 |
2004-11-03 |
Sigma Tau Ind Farmaceuti |
Composizione comprendente statine e acidi grassi omega 3.
|
WO2006017627A2
(en)
|
2004-08-06 |
2006-02-16 |
Barry Sears |
Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
|
RU2382642C2
(ru)
*
|
2004-08-06 |
2010-02-27 |
Трансформ Фармасьютикалз, Инк. |
Новые фармацевтические композиции статина и связанные с ними способы лечения
|
WO2007130714A1
(en)
*
|
2006-02-01 |
2007-11-15 |
Transform Pharmaceuticals, Inc. |
Novel statin pharmaceutical compositions and related methods of treatment
|
WO2007130713A1
(en)
|
2006-02-01 |
2007-11-15 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
US7642287B2
(en)
|
2004-08-06 |
2010-01-05 |
Transform Pharmaceuticals, Inc. |
Statin pharmaceutical compositions and related methods of treatment
|
US20090042979A1
(en)
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
US9452150B2
(en)
|
2004-08-18 |
2016-09-27 |
Mochida Pharmaceutical Co., Ltd. |
Jelly composition
|
DE602005020462D1
(de)
|
2004-08-25 |
2010-05-20 |
Essentialis Inc |
Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen
|
JPWO2006022291A1
(ja)
|
2004-08-27 |
2008-05-08 |
千寿製薬株式会社 |
ドライアイ治療用点眼液
|
KR100545304B1
(ko)
|
2004-09-01 |
2006-05-08 |
주식회사 유니젠 |
아선약을 포함하는 운카리아 속 식물, 또는 이의 황금및/또는 녹차의 배합물을 포함하는 사이클로옥시게나제및/또는 5-리폭시게나제 억제용 조성물
|
WO2006027776A1
(en)
|
2004-09-07 |
2006-03-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
US20080113031A1
(en)
*
|
2004-09-27 |
2008-05-15 |
Joey Moodley |
Minicapsule Formulations
|
WO2006044556A2
(en)
|
2004-10-14 |
2006-04-27 |
Galileo Pharmaceuticals, Inc. |
Dual inhibitors of lipoxygenase for treating diabetes
|
JP5491697B2
(ja)
|
2004-10-15 |
2014-05-14 |
フォトンズ コーポレイション リミテッド |
高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物
|
ES2255426B1
(es)
*
|
2004-10-19 |
2007-08-16 |
Gp Pharm, S.A. |
Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
|
KR101086037B1
(ko)
|
2004-10-27 |
2011-11-22 |
에스케이케미칼주식회사 |
호흡기질환 예방 및 치료에 유용한 산두근 추출물
|
US7531568B2
(en)
|
2004-11-30 |
2009-05-12 |
Plexxikon, Inc. |
PPAR active compounds
|
FR2878747B1
(fr)
|
2004-12-03 |
2007-03-30 |
Pierre Fabre Medicament Sa |
Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
|
US20060211762A1
(en)
|
2004-12-06 |
2006-09-21 |
Rongen Roelof M |
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
|
US20090239927A1
(en)
|
2004-12-06 |
2009-09-24 |
George Bobotas |
Statin and Omega-3 Fatty Acids For Lipid Therapy
|
US20070191467A1
(en)
*
|
2004-12-06 |
2007-08-16 |
Reliant Pharmaceutical, Inc. |
Statin and omega-3 fatty acids for lipid therapy
|
CN101098690A
(zh)
*
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
US20060135610A1
(en)
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
GB2421909A
(en)
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
US20080200707A1
(en)
|
2005-01-04 |
2008-08-21 |
Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. |
Lipotoxicity Relieving Agent
|
EP1834639B8
(en)
|
2005-01-04 |
2016-12-07 |
Mochida Pharmaceutical Co., Ltd. |
Remedial agent for fat toxicity
|
MX2007008331A
(es)
|
2005-01-10 |
2008-01-14 |
Cortendo Invest Ab Publ |
Metodos y composiciones para el tratamiento de diabetes, sindrome metabolico y otras condiciones.
|
US20060172012A1
(en)
|
2005-01-28 |
2006-08-03 |
Finley John W |
Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
|
US20060189682A1
(en)
|
2005-02-02 |
2006-08-24 |
Payne Joseph E |
Water soluble prodrugs of COX-2 inhibitors
|
US20060235009A1
(en)
|
2005-02-08 |
2006-10-19 |
Richard Glickman |
Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
|
CA2598273A1
(en)
|
2005-02-17 |
2006-08-24 |
Merck & Co., Inc. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
US20100254951A1
(en)
|
2005-02-22 |
2010-10-07 |
Mochida Pharmaceutical Co., Ltd. |
Nerve Regeneration Promoting Agent
|
MX2007011031A
(es)
|
2005-03-08 |
2008-04-21 |
Reliant Pharmaceuticals Inc |
Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos.
|
BRPI0607555A2
(pt)
|
2005-04-19 |
2009-09-15 |
Surface Logix Inc |
inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
|
CN102050720B
(zh)
|
2005-05-04 |
2013-03-13 |
普罗诺瓦生物医药挪威公司 |
新的dha衍生物及其作为药物的用途
|
WO2006129193A2
(en)
|
2005-05-27 |
2006-12-07 |
Pfizer Products Inc. |
Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
|
ATE552246T1
(de)
|
2005-05-31 |
2012-04-15 |
Pfizer |
Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
|
JP5134916B2
(ja)
|
2005-07-08 |
2013-01-30 |
持田製薬株式会社 |
心血管イベント発症予防用組成物
|
CA2570763C
(en)
|
2005-07-08 |
2011-08-23 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing onset of cardiovascular events
|
BRPI0612908A2
(pt)
|
2005-07-18 |
2010-12-07 |
Reliant Phamaceuticals Inc |
composições farmacêuticas compreendendo inibidores de absorção de colesterol à base de azetidinona e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
|
US7628027B2
(en)
|
2005-07-19 |
2009-12-08 |
Hussmann Corporation |
Refrigeration system with mechanical subcooling
|
US20090054519A1
(en)
|
2005-07-22 |
2009-02-26 |
Abhijit Ray |
Derivatives of monosaccharides as 5-lipoxygenase inhibitors
|
RU2290185C1
(ru)
|
2005-07-26 |
2006-12-27 |
Дмитрий Николаевич Мясников |
Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
|
WO2007016256A2
(en)
|
2005-07-28 |
2007-02-08 |
Reliant Pharmaceuticals, Inc. |
Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
|
ITMI20051560A1
(it)
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
EP1947942B1
(en)
|
2005-08-18 |
2015-07-29 |
Accelalox, Inc. |
Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
|
RU2302248C2
(ru)
|
2005-08-30 |
2007-07-10 |
Федеральное государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центр |
Средство, обладающее липидкорригирующими, гипокоагуляционными и антиоксидантными свойствами
|
KR100704009B1
(ko)
|
2005-08-30 |
2007-04-04 |
한국화학연구원 |
염증억제 활성을 가지는6-알킬아미노-2-메틸-2'-(n-메틸치환술폰아미도)메틸-2h-1-벤조피란 유도체
|
US7405302B2
(en)
|
2005-10-11 |
2008-07-29 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
EP1951224A2
(en)
|
2005-10-18 |
2008-08-06 |
Aegerion Pharmaceuticals |
Methods for treating disorders associated with hyperlipidemia in a mammal
|
WO2007050271A2
(en)
|
2005-10-25 |
2007-05-03 |
Wyeth |
5-lipoxygenase modulators
|
US20090227602A1
(en)
|
2005-10-28 |
2009-09-10 |
John Griffin |
Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
|
US20070244128A1
(en)
|
2005-11-04 |
2007-10-18 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
US20070219206A1
(en)
|
2005-11-04 |
2007-09-20 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
US20070105793A1
(en)
|
2005-11-04 |
2007-05-10 |
Curt Hendrix |
Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
|
US20070225285A1
(en)
|
2005-11-04 |
2007-09-27 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
US20070104779A1
(en)
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
KR101292573B1
(ko)
|
2005-11-11 |
2013-08-12 |
모치다 세이야쿠 가부시키가이샤 |
젤리 조성물
|
JP2009516003A
(ja)
|
2005-11-15 |
2009-04-16 |
バクスター・インターナショナル・インコーポレイテッド |
リポキシゲナーゼ阻害剤の組成物
|
WO2007058523A1
(en)
|
2005-11-17 |
2007-05-24 |
N.V. Nutricia |
Composition with docosapentaenoic acid
|
WO2007058664A1
(en)
|
2005-11-21 |
2007-05-24 |
Teva Pharmaceutical Industries Ltd. |
Atorvastatin formulation
|
US20070202206A1
(en)
|
2005-11-29 |
2007-08-30 |
Palu Afa K |
Morinda Citrifolia Leaf Juice And Leaf Extract Based Formulations
|
CA2634139C
(en)
|
2005-12-20 |
2015-06-23 |
Cenestra, Llc. |
Omega 3 fatty acid formulations
|
US20070237848A1
(en)
|
2005-12-21 |
2007-10-11 |
Brad Rawson |
MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS
|
ATE509624T1
(de)
|
2005-12-23 |
2011-06-15 |
Nutricia Nv |
Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
|
US20090182022A1
(en)
|
2006-01-05 |
2009-07-16 |
Reliant Pharmaceuticals |
Treatment of Fatty Liver
|
CA2636043A1
(en)
|
2006-01-23 |
2007-08-02 |
Amira Pharmaceuticals, Inc. |
Tricyclic inhibitors of 5-lipoxygenase
|
US20070202159A1
(en)
|
2006-02-02 |
2007-08-30 |
Mathur Rajeev S |
Pharmaceutical composition comprising stabilized statin particles
|
JP5069448B2
(ja)
|
2006-02-07 |
2012-11-07 |
持田製薬株式会社 |
脳卒中再発予防用組成物
|
JP4005104B2
(ja)
|
2006-02-07 |
2007-11-07 |
持田製薬株式会社 |
脳卒中再発予防用組成物
|
US7498359B2
(en)
*
|
2006-02-07 |
2009-03-03 |
Mochida Pharmaceutical., Ltd. |
Composition and method for preventing recurrence of stroke
|
CN101395170A
(zh)
|
2006-02-14 |
2009-03-25 |
英特塞普特药品公司 |
用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
|
WO2007098189A2
(en)
|
2006-02-21 |
2007-08-30 |
Critical Therapeutics, Inc. |
New crystal forms and pharmaceutical compositions of (+) -r-zileuton
|
BRPI0708535A2
(pt)
|
2006-03-03 |
2011-05-31 |
Monsanto Technology Llc |
meios para melhora da saúde cardiovascular
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
EP2081550B2
(en)
|
2006-03-09 |
2021-05-26 |
Reliant Pharmaceuticals, Inc. |
Coating capsules with active pharmaceutical ingredients
|
WO2007128801A1
(en)
|
2006-05-08 |
2007-11-15 |
Novartis Ag |
Combination of organic compounds
|
WO2007142118A1
(ja)
|
2006-05-31 |
2007-12-13 |
Mochida Pharmaceutical Co., Ltd. |
多重リスク患者の心血管イベント発症予防用組成物
|
US20090042835A1
(en)
|
2006-06-02 |
2009-02-12 |
Davis Roger A |
Compositions and methods for ameliorating hyperlipidemia
|
WO2007143164A1
(en)
|
2006-06-02 |
2007-12-13 |
San Diego State University Research Foundation |
Compositions and methods for ameliorating hyperlipidemia
|
US20070292501A1
(en)
|
2006-06-05 |
2007-12-20 |
Udell Ronald G |
Chewable soft gelatin capsules
|
NZ573719A
(en)
|
2006-07-05 |
2011-08-26 |
Photonz Corp Ltd |
Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
|
US20090304784A1
(en)
|
2006-07-28 |
2009-12-10 |
V. Mane Fils |
Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
|
JP5223177B2
(ja)
|
2006-08-23 |
2013-06-26 |
地方独立行政法人北海道立総合研究機構 |
アルミニウム回収用材料、同材料の製造方法及びアルミニウムの回収方法
|
JP2010502702A
(ja)
|
2006-09-05 |
2010-01-28 |
シェーリング コーポレイション |
脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
|
US20080085911A1
(en)
|
2006-10-10 |
2008-04-10 |
Reliant Pharmaceuticals, Inc. |
Statin and omega-3 fatty acids for reduction of apo-b levels
|
EA018734B1
(ru)
|
2006-10-10 |
2013-10-30 |
Релайэнт Фармасьютикалз, Инк. |
СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
|
BRPI0719183A2
(pt)
*
|
2006-10-13 |
2014-06-03 |
Reliant Pharmaceuticals Inc |
Tratamento com antiarrítmicos e ácidos graxos de ômega-3 e um produto de combinação destes
|
WO2008088415A1
(en)
|
2006-10-18 |
2008-07-24 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids for reduction of lp-pla2 levels
|
US20080306154A1
(en)
*
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
US20080125490A1
(en)
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
US20080226758A1
(en)
|
2006-11-28 |
2008-09-18 |
Shixin Deng |
Lipoxygenase and Cyclooxygenase Inhibition
|
US20090042849A1
(en)
|
2006-12-06 |
2009-02-12 |
Yochai Birnbaum |
Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
|
US20080161279A1
(en)
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
JP5345402B2
(ja)
|
2007-01-17 |
2013-11-20 |
持田製薬株式会社 |
血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
|
US8008328B2
(en)
|
2007-01-23 |
2011-08-30 |
Reddy Us Therapeutics, Inc. |
Methods for the treatment of diabetes-associated dyslipdemia
|
US20080185198A1
(en)
|
2007-02-02 |
2008-08-07 |
Steven Mark Jones |
Next generation hybrid III parallel/series hybrid system
|
WO2008100423A1
(en)
|
2007-02-09 |
2008-08-21 |
Sirtris Pharmaceuticals, Inc. |
Gut microsomal triglyceride transport protein inhibitors
|
CA2672513C
(en)
|
2007-02-15 |
2010-05-25 |
Centre De Recherche Sur Les Biotechnologies Marines |
Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
|
US20100055175A1
(en)
|
2007-03-06 |
2010-03-04 |
James Nugent |
Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
|
WO2008115529A1
(en)
|
2007-03-20 |
2008-09-25 |
Reliant Pharmaceuticals, Inc. |
Compositions comprising omega-3 fatty acids and cetp inhibitors
|
US8048880B2
(en)
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
WO2008145170A1
(de)
|
2007-05-31 |
2008-12-04 |
Siemens Aktiengesellschaft |
Verfahren zum konfigurieren einer automatisierungsanlage
|
US20080299187A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Joar Opheim |
Substances for Reducing Occurence of Major Cardiac Events in Humans
|
US20090118503A1
(en)
|
2007-06-20 |
2009-05-07 |
Kevin Sprott |
Faah inhibitors
|
WO2009004999A1
(ja)
|
2007-06-29 |
2009-01-08 |
Takeda Pharmaceutical Company Limited |
シームレスカプセル
|
US20090092595A1
(en)
|
2007-07-13 |
2009-04-09 |
Regents Of The University Of California |
Suppression of sPLA2-integrin binding for treating an inflammatory condition
|
US20090062369A1
(en)
|
2007-08-31 |
2009-03-05 |
Joaquim Trias |
Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
|
EP2205231A1
(en)
|
2007-10-01 |
2010-07-14 |
NeuroSearch A/S |
Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
|
AU2008343689A1
(en)
|
2007-12-20 |
2009-07-09 |
Abbott Laboratories |
Stable nutritional powder
|
US8361534B2
(en)
|
2007-12-20 |
2013-01-29 |
Abbott Laboratories |
Stable nutritional powder
|
US20100285121A1
(en)
|
2008-01-10 |
2010-11-11 |
Takeda Pharmaceutical Company Limited |
Capsule Formulation
|
US20090182049A1
(en)
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
CA2724463C
(en)
|
2008-05-15 |
2017-10-03 |
Pronova Biopharma Norge As |
Krill oil process
|
CA2724983A1
(en)
|
2008-05-20 |
2009-11-26 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing cardiovascular event in high-risk patient
|
JPWO2009151125A1
(ja)
|
2008-06-13 |
2011-11-17 |
持田製薬株式会社 |
肝障害の診断及び治療
|
US20110082119A1
(en)
|
2008-06-13 |
2011-04-07 |
Takashi Yano |
Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
|
JPWO2009154230A1
(ja)
|
2008-06-17 |
2011-12-01 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防/改善・治療薬
|
EP2308493A4
(en)
|
2008-07-07 |
2013-05-01 |
Mochida Pharm Co Ltd |
ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
|
PL2334295T3
(pl)
|
2008-09-02 |
2017-12-29 |
Amarin Pharmaceuticals Ltd |
Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
|
EP2343066A4
(en)
|
2008-09-30 |
2012-08-29 |
Mochida Pharm Co Ltd |
THERAPEUTIC AGENT FOR HEPATITIS C
|
WO2010040012A1
(en)
|
2008-10-01 |
2010-04-08 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
WO2010080976A1
(en)
|
2009-01-09 |
2010-07-15 |
Sdg, Inc. (An Ohio Corporation) |
Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
|
CA2750561C
(en)
|
2009-01-26 |
2017-10-10 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
MX2011008448A
(es)
|
2009-02-10 |
2012-02-28 |
Amarin Pharma Inc |
Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
|
EP2405902B1
(en)
|
2009-03-09 |
2021-07-21 |
Basf As |
Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
|
US8241672B2
(en)
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
WO2010117951A1
(en)
|
2009-04-06 |
2010-10-14 |
The Regents Of The University Of California |
Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
|
EP2424521A4
(en)
*
|
2009-04-29 |
2015-03-04 |
Amarin Pharmaceuticals Ie Ltd |
PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
|
CN102458109B
(zh)
|
2009-04-29 |
2015-02-11 |
阿马里纳制药公司 |
稳定的药物组合物和使用其的方法
|
EP2433630A4
(en)
|
2009-05-22 |
2014-01-08 |
Mochida Pharm Co Ltd |
SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3
|
KR102012111B1
(ko)
|
2009-06-15 |
2019-08-19 |
아마린 파마, 인크. |
병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
|
RU2402326C1
(ru)
|
2009-06-22 |
2010-10-27 |
Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) |
Способ коррекции инсулинорезистентности при метаболическом синдроме
|
US8557275B2
(en)
|
2009-07-23 |
2013-10-15 |
U.S. Nutraceuticals, LLC |
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
|
CN102724877B
(zh)
|
2009-09-01 |
2015-05-13 |
凯特贝希制药公司 |
脂肪酸烟酸缀合物及其用途
|
SG10201405994UA
(en)
|
2009-09-23 |
2014-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
|
US9060981B2
(en)
|
2009-10-16 |
2015-06-23 |
Mochida Pharmaceutical Co., Ltd. |
Marker associated with non-alcoholic steatohepatitis
|
US9717703B2
(en)
|
2009-10-16 |
2017-08-01 |
Glaxosmithkline Llc |
Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
|
JP5771627B2
(ja)
|
2010-01-08 |
2015-09-02 |
カタバシス ファーマシューティカルズ,インコーポレイテッド |
脂肪酸フマル酸塩誘導体およびそれらの使用
|
WO2011087981A2
(en)
|
2010-01-15 |
2011-07-21 |
E. I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
EP2542060B1
(en)
|
2010-03-04 |
2019-10-02 |
Amarin Pharmaceuticals Ireland Limited |
Compositions for treating and/or preventing cardiovascular disease
|
US8846321B2
(en)
|
2010-03-12 |
2014-09-30 |
President And Fellows Of Harvard College |
Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
|
US8663704B2
(en)
|
2010-04-30 |
2014-03-04 |
U.S. Nutraceuticals, LLC |
Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
|
EP2566350B1
(en)
|
2010-05-05 |
2016-05-04 |
St. Giles Foods Limited |
Edible compositions and methods of manufacturing edible compositions
|
CA2803558C
(en)
|
2010-06-30 |
2018-05-29 |
Mochida Pharmaceutical Co., Ltd. |
.omega.3 fatty acid compound preparation
|
AR082930A1
(es)
|
2010-09-08 |
2013-01-16 |
Pronova Biopharma Norge As |
Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
|
US10557856B2
(en)
|
2010-09-24 |
2020-02-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Biomarkers of renal injury
|
US20130260403A1
(en)
|
2010-10-20 |
2013-10-03 |
GlycoMark Inc. |
Identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
|
CN103338762B
(zh)
|
2010-11-09 |
2015-03-25 |
持田制药株式会社 |
血糖值上升抑制剂
|
NZ712068A
(en)
|
2010-11-29 |
2017-03-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
EP2471537A1
(en)
|
2010-12-30 |
2012-07-04 |
PregLem S.A. |
Treatment of pain associated with dislocation of basal endometrium
|
EP2502506A1
(en)
|
2011-03-21 |
2012-09-26 |
Abbott Laboratories |
Methods for improving bone health in infants using long chain polyunsaturated fatty acids
|
KR101310710B1
(ko)
|
2011-03-23 |
2013-09-27 |
한미약품 주식회사 |
오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물
|
US20120264824A1
(en)
|
2011-04-15 |
2012-10-18 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US8660662B2
(en)
|
2011-04-22 |
2014-02-25 |
Medtronic, Inc. |
Low impedance, low modulus wire configurations for a medical device
|
ES2833468T3
(es)
|
2011-04-27 |
2021-06-15 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de apolipoproteína CIII (APOCIII)
|
WO2013040507A1
(en)
|
2011-09-15 |
2013-03-21 |
Omthera Pharmaceuticals, Inc. |
Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
EP2792746A4
(en)
|
2011-12-12 |
2015-09-16 |
Nat Cerebral & Cardiovascular Ct |
OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
|
WO2013103958A1
(en)
|
2012-01-06 |
2013-07-11 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
WO2013136277A1
(en)
|
2012-03-13 |
2013-09-19 |
Unimark Remedies Ltd. |
Pharmaceutical compositions for treatment of cardiovascular diseases
|
IL249821B
(en)
|
2012-03-30 |
2019-04-30 |
Sancilio & Company Inc |
Omega-3 fatty acid ester compositions
|
JP6173437B2
(ja)
|
2012-05-07 |
2017-08-02 |
オムセラ・ファーマシューティカルズ・インコーポレイテッド |
スタチン及びω−3脂肪酸の組成物
|
KR102125034B1
(ko)
|
2012-05-15 |
2020-06-19 |
모치다 세이야쿠 가부시키가이샤 |
고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제
|
EP2854951B1
(de)
|
2012-05-30 |
2016-09-07 |
Clariant International Ltd. |
Zusammensetzung enthaltend aminosäuretenside, betaine und n-methyl-n-acylglucamine mit verbesserter schaumqualität und höherer viskosität
|
US20130324607A1
(en)
|
2012-06-05 |
2013-12-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypercholesterolemia
|
US20140080850A1
(en)
|
2012-06-05 |
2014-03-20 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
|
JP2015520194A
(ja)
|
2012-06-07 |
2015-07-16 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物標的指向化のためのナノ療法
|
EP2861227A4
(en)
|
2012-06-17 |
2016-01-27 |
Matinas Biopharma Inc |
OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
|
US20140004183A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating cardiovascular disease in statin-tolerant subjects
|
US20140005265A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating hypertriglyceridemia
|
RU2015102808A
(ru)
|
2012-06-29 |
2016-08-20 |
Амарин Фармасьютикалз Айрлэнд Лимитед |
Способы лечения педиатрического метаболического синдрома
|
SG11201408769QA
(en)
|
2012-06-29 |
2015-01-29 |
Amarin Pharmaceuticals Ie Ltd |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
WO2014004993A2
(en)
|
2012-06-29 |
2014-01-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing ldl-p
|
WO2014050692A1
(ja)
|
2012-09-28 |
2014-04-03 |
持田製薬株式会社 |
糖尿病新規発症低減用組成物
|
EP2719382A1
(en)
|
2012-10-12 |
2014-04-16 |
Mochida Pharmaceutical Co., Ltd. |
Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
|
US9486433B2
(en)
|
2012-10-12 |
2016-11-08 |
Mochida Pharmaceuticals Co. Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US20140142127A1
(en)
|
2012-10-23 |
2014-05-22 |
Almburg, Llc |
Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US8703188B1
(en)
*
|
2012-11-19 |
2014-04-22 |
Azanta A/S |
Dispersible tablet
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140213648A1
(en)
|
2012-12-31 |
2014-07-31 |
Amarin Pharmaceuticals Ireland Limited |
Methods of increasing epa blood levels
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US20140221676A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US20140221452A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
|
US20140221358A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US20140242216A1
(en)
|
2013-02-24 |
2014-08-28 |
Mead Johnson Nutrition Company |
Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
|
US20140249214A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of warfarin and ethyl eicosapentaenoate
|
WO2014134466A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited. |
Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
|
US20140249220A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
|
US20140249225A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US9661874B2
(en)
|
2013-03-11 |
2017-05-30 |
Mead Johnson Nutrition Company |
Nutritional compositions containing structured fat globules and uses thereof
|
US20140255537A1
(en)
|
2013-03-11 |
2014-09-11 |
Mead Johnson Nutrition Company |
Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140275252A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating traumatic brain injury
|
US20140271907A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10441560B2
(en)
|
2013-03-15 |
2019-10-15 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
WO2014142364A2
(en)
|
2013-03-15 |
2014-09-18 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US20140322314A1
(en)
|
2013-04-29 |
2014-10-30 |
Matinas Biopharma, Inc. |
Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
|
KR102240429B1
(ko)
|
2013-05-06 |
2021-04-15 |
한미약품 주식회사 |
로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
|
US20140357717A1
(en)
|
2013-06-04 |
2014-12-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
SG11201510011VA
(en)
|
2013-06-07 |
2016-01-28 |
California Inst Biomedical Res |
Small molecule inhibitors of fibrosis
|
WO2014205310A2
(en)
|
2013-06-21 |
2014-12-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Techniques for predicting cardiac arrhythmias based on signals from leads of electrocardiography
|
SG11201600337PA
(en)
|
2013-07-18 |
2016-02-26 |
Mochida Pharm Co Ltd |
SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
|
CA2918336C
(en)
|
2013-07-18 |
2022-05-24 |
Mochida Pharmaceutical Co., Ltd. |
Self-emulsifying composition of .omega.3 fatty acid
|
WO2015021141A1
(en)
|
2013-08-06 |
2015-02-12 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
|
US20150051282A1
(en)
|
2013-08-14 |
2015-02-19 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US20150073050A1
(en)
|
2013-09-09 |
2015-03-12 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
|
EP3054940B1
(en)
|
2013-10-07 |
2020-09-23 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
WO2015066512A1
(en)
|
2013-10-31 |
2015-05-07 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
RS59637B1
(sr)
|
2014-04-11 |
2020-01-31 |
Cymabay Therapeutics Inc |
Tretiranje nafld i nash
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
JP2017531306A
(ja)
|
2014-08-01 |
2017-10-19 |
ウェスタン・ミシガン・ユニバーシティ・リサーチ・ファウンデイションWestern Michigan University Research Foundation |
自立式電子デバイス
|
CA2974321C
(en)
|
2015-01-21 |
2023-09-05 |
Mochida Pharmaceutical Co., Ltd. |
Self-emulsifying composition of .omega.-3 fatty acid
|
US20180015038A1
(en)
|
2015-01-21 |
2018-01-18 |
Mochida Pharmaceutical Co., Ltd. |
Omega-3 fatty acid self-emulsifying composition
|
US20180028480A1
(en)
|
2015-03-02 |
2018-02-01 |
Richard Preston Mason |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US20170151202A1
(en)
|
2015-09-09 |
2017-06-01 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
HUE053081T2
(hu)
|
2016-07-29 |
2021-06-28 |
Kowa Co |
Módszerek kardiovaszkuláris események megelõzésére megmaradó kockázatú diszlipidémiás populációkban
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
TW201900160A
(zh)
|
2017-05-19 |
2019-01-01 |
愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 |
用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
|
US20190054054A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods reducing or preventing oxidation of high density lipoprotein (HDL)
|
US20190054058A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of Treating or Preventing Bone Loss
|
US20190209506A1
(en)
|
2018-01-09 |
2019-07-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
US20190275057A1
(en)
|
2018-03-06 |
2019-09-12 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
|
EP3836914A4
(en)
|
2018-08-17 |
2022-05-18 |
Amarin Pharmaceuticals Ireland Limited |
METHODS OF REDUCING THE NEED FOR PERIPHERAL ARTERIAL REVASCULARIZATION IN A SUBJECT TREATED WITH STATINS
|
KR102296068B1
(ko)
|
2018-09-24 |
2021-09-02 |
애머린 파마슈티칼스 아일랜드 리미티드 |
대상체에서 심혈관 사건의 위험도를 감소시키는 방법
|
WO2020065402A1
(en)
|
2018-09-26 |
2020-04-02 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
|
TW202045154A
(zh)
|
2019-02-15 |
2020-12-16 |
愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 |
藉由增加血清及血漿epa及dpa含量來降低經他汀治療之受試者之心血管事件之風險的方法
|
KR20220041871A
(ko)
|
2019-08-01 |
2022-04-01 |
에보니크 오퍼레이션즈 게엠베하 |
오메가-3 지방산 염 및 보스웰리아 종으로부터의 검 수지의 추출물을 포함하는 제제
|
KR20220122616A
(ko)
|
2019-11-12 |
2022-09-02 |
애머린 파마슈티칼스 아일랜드 리미티드 |
심방 세동 및/또는 심방 조동을 갖는 대상체에서 심혈관 사건의 위험을 감소시키는 방법
|